Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC in NAFLD
NCT05589584Phase 3Completed
- Sponsor
- Ain Shams University
- Start
- Nov 2022
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of acetylcysteine in non-alcoholic fatty liver disease (NAFLD) (2 arms), sponsored by Ain Shams University. Primary endpoint: Serum Leptin Level at 3 months. Started Nov 2022; status: completed.
02
Drugs
acetylcysteine
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT05589584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05589584.